Literature DB >> 6849767

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

M Eichelbaum, L Bertilsson, J Säwe.   

Abstract

Thirty-five healthy subjects who had been classified as extensive or poor metabolizers of both sparteine and debrisoquine were given a single oral dose of antipyrine. Saliva concentration of antipyrine and urinary excretion of its three major oxidation metabolites were measured. All the parameters of antipyrine metabolism which were estimated had similar distributions in both the 28 EM and 7 PM genetic phenotypes defined by the metabolism of sparteine and debrisoquine. The clearance of antipyrine by the formation of 4-hydroxy-antipyrine and 3-hydroxy-antipyrine respectively were closely correlated (r = 0.83, P less than 0.001) and both were significantly higher in smokers than in non-smokers. Demethylation of antipyrine also seemed to be influenced by smoking, but not to a statistically significant extent. These findings confirm the influence of the environmental factor of smoking in antipyrine oxidative biotransformations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849767      PMCID: PMC1427783          DOI: 10.1111/j.1365-2125.1983.tb01505.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 2.  Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.

Authors:  J R Idle; R L Smith
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

Review 3.  Genetic and environmental factors affecting drug disposition in man.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

Review 4.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

5.  Genetic control of drug levels in man: antipyrine.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-07-05       Impact factor: 47.728

6.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

7.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Deficient metabolism of debrisoquine and sparteine.

Authors:  T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.

Authors:  M Eichelbaum; H R Ochs; G Roberts; A Somogyi
Journal:  Arzneimittelforschung       Date:  1982
View more
  14 in total

1.  Biliary excretion of antipyrine and its metabolites after cholecystectomy.

Authors:  H Mönig; J Wilhelmy; S John; E E Ohnhaus
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

2.  Plasma antipyrine half-life can be determined from urine data.

Authors:  J O Atiba; G Taylor; R A Pershe; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

3.  Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.

Authors:  I Walter-Sack; M Eichelbaum; J X de Vries; E Weber
Journal:  Klin Wochenschr       Date:  1988-11-01

4.  Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine.

Authors:  G T Blyden; D J Greenblatt; B W LeDuc; J M Scavone
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Adverse effects from metoprolol are not generally associated with oxidation status.

Authors:  D W Clark; A K Morgan; H Waal-Manning
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

6.  Measurement of antipyrine half-life from urinary drug concentrations.

Authors:  G Taylor; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

7.  Antipyrine metabolism is not affected by terbinafine, a new antifungal agent.

Authors:  R Seyffer; M Eichelbaum; J C Jensen; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  Variation of benzbromarone elimination in man--a population study.

Authors:  I Walter-Sack; U Gresser; M Adjan; I Kamilli; A Ittensohn; J X de Vries; E Weber; N Zöllner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

9.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

10.  Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine.

Authors:  B Gachályi; A Vas; K Csillag; B Nagy; F Kocsis; A Káldor
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.